Clinical experience of QuantiFERON®-TB Gold testing in patients with psoriasis treated with tumour necrosis factor blockers in Taiwan
Summary Background In Taiwan, an intermediate tuberculosis burden country, around 9·3% of patients with rheumatoid arthritis treated with adalimumab develop tuberculosis despite prescreening with the tuberculin skin test. Within the Asia‐Pacific region, the tuberculosis risk in patients with psoria...
Gespeichert in:
| Veröffentlicht in: | British journal of dermatology (1951) 2011-03, Vol.164 (3), p.553-559 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 559 |
|---|---|
| container_issue | 3 |
| container_start_page | 553 |
| container_title | British journal of dermatology (1951) |
| container_volume | 164 |
| creator | Chiu, H-Y. Hsueh, P-R. Tsai, T-F. |
| description | Summary
Background In Taiwan, an intermediate tuberculosis burden country, around 9·3% of patients with rheumatoid arthritis treated with adalimumab develop tuberculosis despite prescreening with the tuberculin skin test. Within the Asia‐Pacific region, the tuberculosis risk in patients with psoriasis who use tumour necrosis factor (TNF) blockers is unknown.
Objectives This study reports the use of QuantiFERON®‐TB Gold (QFT‐G) (Cellestis, Melbourne, Vic., Australia) as a screening method for latent tuberculosis infection (LTBI) in patients with psoriasis.
Methods This retrospective review evaluated 216 patients with psoriasis in whom TNF blockers were considered between 2004 and 2009 in a tertiary referral hospital in Taiwan. Beginning in 2007, QFT‐G was performed on all patients who were candidates for TNF blockers.
Results Seventeen patients who used TNF blockers for less than 4 weeks were excluded. Of the 147 assessed patients receiving TNF blockers, 110 (75%) underwent QFT‐G tests. A total of 126 (86%) patients used etanercept and 40 (27%) patients used adalimumab. Nineteen patients switched between both. Overall, patients had a median of 24 weeks (range 4–307) exposure to TNF blockers. Twelve patients (11%) who were treated with TNF blockers and eight (15%) without TNF blockers had positive QFT‐G results. Of all TNF blocker users, only one patient (0·68%) developed tuberculosis.
Conclusions QFT‐G can be used to screen for LTBI in a tuberculosis endemic area where bacille Calmette–Guérin vaccination coverage is high. Isoniazid prophylaxis is recommended for those who have positive QFT‐G test results. |
| doi_str_mv | 10.1111/j.1365-2133.2010.10137.x |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_855910441</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>855910441</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3887-25e61b7e10e5b8a0a3aa79c9cc075edeca708f841d59abf02493c90a0a677a0e3</originalsourceid><addsrcrecordid>eNpFkdFu0zAUhi0EYmXwCsg3iKsUO47j5AaJla0DTRuriuDOOnFPwF2aZLajdi_A4_AQPBnOWopvbJ3_0yf5_IRQzqY8nnfrKRe5TFIuxDRl45Rxoaa7J2RyDJ6SCWNMJazMxQl54f2aRYhJ9pycpJwVQmZ8Qn7NGttaAw3FXY_OYmuQdjW9HaAN9uJ8cXP953eyPKPzrlnRgD7Y9ge1Le0hRDh4urXhJ-195yx462lwCAFX-3EYNt3gaIvGdWNYgwmdo1XTmTt0fvQswW6hfUme1dB4fHW4T8nXi_Pl7DK5upl_mn24SowoCpWkEnNeKeQMZVUAAwGgSlMaw5TEFRpQrKiLjK9kCVXN0qwUpmQRzJUChuKUvN17e9fdD_E3emO9waaBFrvB60LKkrMs45F8fSCHaoMr3Tu7Afeg_60uAm8OAPi4v9pBa6z_z4mySDNVRu79ntvaBh-OOWd6rFKv9diYHhvTY5X6sUq902efPz4-oyDZC6wPuDsKwN3pXAkl9bfruV58zy-Xt7MveiH-Ai6No1M</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>855910441</pqid></control><display><type>article</type><title>Clinical experience of QuantiFERON®-TB Gold testing in patients with psoriasis treated with tumour necrosis factor blockers in Taiwan</title><source>MEDLINE</source><source>Access via Wiley Online Library</source><source>Oxford University Press Journals All Titles (1996-Current)</source><creator>Chiu, H-Y. ; Hsueh, P-R. ; Tsai, T-F.</creator><creatorcontrib>Chiu, H-Y. ; Hsueh, P-R. ; Tsai, T-F.</creatorcontrib><description>Summary
Background In Taiwan, an intermediate tuberculosis burden country, around 9·3% of patients with rheumatoid arthritis treated with adalimumab develop tuberculosis despite prescreening with the tuberculin skin test. Within the Asia‐Pacific region, the tuberculosis risk in patients with psoriasis who use tumour necrosis factor (TNF) blockers is unknown.
Objectives This study reports the use of QuantiFERON®‐TB Gold (QFT‐G) (Cellestis, Melbourne, Vic., Australia) as a screening method for latent tuberculosis infection (LTBI) in patients with psoriasis.
Methods This retrospective review evaluated 216 patients with psoriasis in whom TNF blockers were considered between 2004 and 2009 in a tertiary referral hospital in Taiwan. Beginning in 2007, QFT‐G was performed on all patients who were candidates for TNF blockers.
Results Seventeen patients who used TNF blockers for less than 4 weeks were excluded. Of the 147 assessed patients receiving TNF blockers, 110 (75%) underwent QFT‐G tests. A total of 126 (86%) patients used etanercept and 40 (27%) patients used adalimumab. Nineteen patients switched between both. Overall, patients had a median of 24 weeks (range 4–307) exposure to TNF blockers. Twelve patients (11%) who were treated with TNF blockers and eight (15%) without TNF blockers had positive QFT‐G results. Of all TNF blocker users, only one patient (0·68%) developed tuberculosis.
Conclusions QFT‐G can be used to screen for LTBI in a tuberculosis endemic area where bacille Calmette–Guérin vaccination coverage is high. Isoniazid prophylaxis is recommended for those who have positive QFT‐G test results.</description><identifier>ISSN: 0007-0963</identifier><identifier>EISSN: 1365-2133</identifier><identifier>DOI: 10.1111/j.1365-2133.2010.10137.x</identifier><identifier>PMID: 21083541</identifier><identifier>CODEN: BJDEAZ</identifier><language>eng</language><publisher>Oxford, UK: Blackwell Publishing Ltd</publisher><subject>Adalimumab ; Adolescent ; Adult ; Aged ; Aged, 80 and over ; Anti-Inflammatory Agents - therapeutic use ; Antibodies, Monoclonal - therapeutic use ; Antibodies, Monoclonal, Humanized ; Biological and medical sciences ; Child ; Dermatology ; Etanercept ; Female ; Humans ; Immunoglobulin G - therapeutic use ; Latent Tuberculosis - diagnosis ; Male ; Mass Screening - methods ; Medical sciences ; Middle Aged ; Psoriasis - complications ; Psoriasis - drug therapy ; Psoriasis. Parapsoriasis. Lichen ; Receptors, Tumor Necrosis Factor - therapeutic use ; Retrospective Studies ; Taiwan ; Tuberculin Test - methods ; Tumor Necrosis Factor-alpha - antagonists & inhibitors ; Young Adult</subject><ispartof>British journal of dermatology (1951), 2011-03, Vol.164 (3), p.553-559</ispartof><rights>2011 The Authors. BJD © 2011 British Association of Dermatologists</rights><rights>2015 INIST-CNRS</rights><rights>2011 The Authors. BJD © 2011 British Association of Dermatologists.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3887-25e61b7e10e5b8a0a3aa79c9cc075edeca708f841d59abf02493c90a0a677a0e3</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fj.1365-2133.2010.10137.x$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fj.1365-2133.2010.10137.x$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1417,27924,27925,45574,45575</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=23982479$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/21083541$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Chiu, H-Y.</creatorcontrib><creatorcontrib>Hsueh, P-R.</creatorcontrib><creatorcontrib>Tsai, T-F.</creatorcontrib><title>Clinical experience of QuantiFERON®-TB Gold testing in patients with psoriasis treated with tumour necrosis factor blockers in Taiwan</title><title>British journal of dermatology (1951)</title><addtitle>Br J Dermatol</addtitle><description>Summary
Background In Taiwan, an intermediate tuberculosis burden country, around 9·3% of patients with rheumatoid arthritis treated with adalimumab develop tuberculosis despite prescreening with the tuberculin skin test. Within the Asia‐Pacific region, the tuberculosis risk in patients with psoriasis who use tumour necrosis factor (TNF) blockers is unknown.
Objectives This study reports the use of QuantiFERON®‐TB Gold (QFT‐G) (Cellestis, Melbourne, Vic., Australia) as a screening method for latent tuberculosis infection (LTBI) in patients with psoriasis.
Methods This retrospective review evaluated 216 patients with psoriasis in whom TNF blockers were considered between 2004 and 2009 in a tertiary referral hospital in Taiwan. Beginning in 2007, QFT‐G was performed on all patients who were candidates for TNF blockers.
Results Seventeen patients who used TNF blockers for less than 4 weeks were excluded. Of the 147 assessed patients receiving TNF blockers, 110 (75%) underwent QFT‐G tests. A total of 126 (86%) patients used etanercept and 40 (27%) patients used adalimumab. Nineteen patients switched between both. Overall, patients had a median of 24 weeks (range 4–307) exposure to TNF blockers. Twelve patients (11%) who were treated with TNF blockers and eight (15%) without TNF blockers had positive QFT‐G results. Of all TNF blocker users, only one patient (0·68%) developed tuberculosis.
Conclusions QFT‐G can be used to screen for LTBI in a tuberculosis endemic area where bacille Calmette–Guérin vaccination coverage is high. Isoniazid prophylaxis is recommended for those who have positive QFT‐G test results.</description><subject>Adalimumab</subject><subject>Adolescent</subject><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Anti-Inflammatory Agents - therapeutic use</subject><subject>Antibodies, Monoclonal - therapeutic use</subject><subject>Antibodies, Monoclonal, Humanized</subject><subject>Biological and medical sciences</subject><subject>Child</subject><subject>Dermatology</subject><subject>Etanercept</subject><subject>Female</subject><subject>Humans</subject><subject>Immunoglobulin G - therapeutic use</subject><subject>Latent Tuberculosis - diagnosis</subject><subject>Male</subject><subject>Mass Screening - methods</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Psoriasis - complications</subject><subject>Psoriasis - drug therapy</subject><subject>Psoriasis. Parapsoriasis. Lichen</subject><subject>Receptors, Tumor Necrosis Factor - therapeutic use</subject><subject>Retrospective Studies</subject><subject>Taiwan</subject><subject>Tuberculin Test - methods</subject><subject>Tumor Necrosis Factor-alpha - antagonists & inhibitors</subject><subject>Young Adult</subject><issn>0007-0963</issn><issn>1365-2133</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2011</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpFkdFu0zAUhi0EYmXwCsg3iKsUO47j5AaJla0DTRuriuDOOnFPwF2aZLajdi_A4_AQPBnOWopvbJ3_0yf5_IRQzqY8nnfrKRe5TFIuxDRl45Rxoaa7J2RyDJ6SCWNMJazMxQl54f2aRYhJ9pycpJwVQmZ8Qn7NGttaAw3FXY_OYmuQdjW9HaAN9uJ8cXP953eyPKPzrlnRgD7Y9ge1Le0hRDh4urXhJ-195yx462lwCAFX-3EYNt3gaIvGdWNYgwmdo1XTmTt0fvQswW6hfUme1dB4fHW4T8nXi_Pl7DK5upl_mn24SowoCpWkEnNeKeQMZVUAAwGgSlMaw5TEFRpQrKiLjK9kCVXN0qwUpmQRzJUChuKUvN17e9fdD_E3emO9waaBFrvB60LKkrMs45F8fSCHaoMr3Tu7Afeg_60uAm8OAPi4v9pBa6z_z4mySDNVRu79ntvaBh-OOWd6rFKv9diYHhvTY5X6sUq902efPz4-oyDZC6wPuDsKwN3pXAkl9bfruV58zy-Xt7MveiH-Ai6No1M</recordid><startdate>201103</startdate><enddate>201103</enddate><creator>Chiu, H-Y.</creator><creator>Hsueh, P-R.</creator><creator>Tsai, T-F.</creator><general>Blackwell Publishing Ltd</general><general>Wiley-Blackwell</general><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7X8</scope></search><sort><creationdate>201103</creationdate><title>Clinical experience of QuantiFERON®-TB Gold testing in patients with psoriasis treated with tumour necrosis factor blockers in Taiwan</title><author>Chiu, H-Y. ; Hsueh, P-R. ; Tsai, T-F.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3887-25e61b7e10e5b8a0a3aa79c9cc075edeca708f841d59abf02493c90a0a677a0e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2011</creationdate><topic>Adalimumab</topic><topic>Adolescent</topic><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Anti-Inflammatory Agents - therapeutic use</topic><topic>Antibodies, Monoclonal - therapeutic use</topic><topic>Antibodies, Monoclonal, Humanized</topic><topic>Biological and medical sciences</topic><topic>Child</topic><topic>Dermatology</topic><topic>Etanercept</topic><topic>Female</topic><topic>Humans</topic><topic>Immunoglobulin G - therapeutic use</topic><topic>Latent Tuberculosis - diagnosis</topic><topic>Male</topic><topic>Mass Screening - methods</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Psoriasis - complications</topic><topic>Psoriasis - drug therapy</topic><topic>Psoriasis. Parapsoriasis. Lichen</topic><topic>Receptors, Tumor Necrosis Factor - therapeutic use</topic><topic>Retrospective Studies</topic><topic>Taiwan</topic><topic>Tuberculin Test - methods</topic><topic>Tumor Necrosis Factor-alpha - antagonists & inhibitors</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Chiu, H-Y.</creatorcontrib><creatorcontrib>Hsueh, P-R.</creatorcontrib><creatorcontrib>Tsai, T-F.</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection><jtitle>British journal of dermatology (1951)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Chiu, H-Y.</au><au>Hsueh, P-R.</au><au>Tsai, T-F.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Clinical experience of QuantiFERON®-TB Gold testing in patients with psoriasis treated with tumour necrosis factor blockers in Taiwan</atitle><jtitle>British journal of dermatology (1951)</jtitle><addtitle>Br J Dermatol</addtitle><date>2011-03</date><risdate>2011</risdate><volume>164</volume><issue>3</issue><spage>553</spage><epage>559</epage><pages>553-559</pages><issn>0007-0963</issn><eissn>1365-2133</eissn><coden>BJDEAZ</coden><abstract>Summary
Background In Taiwan, an intermediate tuberculosis burden country, around 9·3% of patients with rheumatoid arthritis treated with adalimumab develop tuberculosis despite prescreening with the tuberculin skin test. Within the Asia‐Pacific region, the tuberculosis risk in patients with psoriasis who use tumour necrosis factor (TNF) blockers is unknown.
Objectives This study reports the use of QuantiFERON®‐TB Gold (QFT‐G) (Cellestis, Melbourne, Vic., Australia) as a screening method for latent tuberculosis infection (LTBI) in patients with psoriasis.
Methods This retrospective review evaluated 216 patients with psoriasis in whom TNF blockers were considered between 2004 and 2009 in a tertiary referral hospital in Taiwan. Beginning in 2007, QFT‐G was performed on all patients who were candidates for TNF blockers.
Results Seventeen patients who used TNF blockers for less than 4 weeks were excluded. Of the 147 assessed patients receiving TNF blockers, 110 (75%) underwent QFT‐G tests. A total of 126 (86%) patients used etanercept and 40 (27%) patients used adalimumab. Nineteen patients switched between both. Overall, patients had a median of 24 weeks (range 4–307) exposure to TNF blockers. Twelve patients (11%) who were treated with TNF blockers and eight (15%) without TNF blockers had positive QFT‐G results. Of all TNF blocker users, only one patient (0·68%) developed tuberculosis.
Conclusions QFT‐G can be used to screen for LTBI in a tuberculosis endemic area where bacille Calmette–Guérin vaccination coverage is high. Isoniazid prophylaxis is recommended for those who have positive QFT‐G test results.</abstract><cop>Oxford, UK</cop><pub>Blackwell Publishing Ltd</pub><pmid>21083541</pmid><doi>10.1111/j.1365-2133.2010.10137.x</doi><tpages>7</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0007-0963 |
| ispartof | British journal of dermatology (1951), 2011-03, Vol.164 (3), p.553-559 |
| issn | 0007-0963 1365-2133 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_855910441 |
| source | MEDLINE; Access via Wiley Online Library; Oxford University Press Journals All Titles (1996-Current) |
| subjects | Adalimumab Adolescent Adult Aged Aged, 80 and over Anti-Inflammatory Agents - therapeutic use Antibodies, Monoclonal - therapeutic use Antibodies, Monoclonal, Humanized Biological and medical sciences Child Dermatology Etanercept Female Humans Immunoglobulin G - therapeutic use Latent Tuberculosis - diagnosis Male Mass Screening - methods Medical sciences Middle Aged Psoriasis - complications Psoriasis - drug therapy Psoriasis. Parapsoriasis. Lichen Receptors, Tumor Necrosis Factor - therapeutic use Retrospective Studies Taiwan Tuberculin Test - methods Tumor Necrosis Factor-alpha - antagonists & inhibitors Young Adult |
| title | Clinical experience of QuantiFERON®-TB Gold testing in patients with psoriasis treated with tumour necrosis factor blockers in Taiwan |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-04T06%3A42%3A59IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Clinical%20experience%20of%20QuantiFERON%C2%AE-TB%20Gold%20testing%20in%20patients%20with%20psoriasis%20treated%20with%20tumour%20necrosis%20factor%20blockers%20in%20Taiwan&rft.jtitle=British%20journal%20of%20dermatology%20(1951)&rft.au=Chiu,%20H-Y.&rft.date=2011-03&rft.volume=164&rft.issue=3&rft.spage=553&rft.epage=559&rft.pages=553-559&rft.issn=0007-0963&rft.eissn=1365-2133&rft.coden=BJDEAZ&rft_id=info:doi/10.1111/j.1365-2133.2010.10137.x&rft_dat=%3Cproquest_pubme%3E855910441%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=855910441&rft_id=info:pmid/21083541&rfr_iscdi=true |